SCHEMBL67257

SCHEMBL67257

[c]1ccc(C23CC4CC(CC(C4)C2)C3)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.57
ALDH1A1 P00352 3/20 0.57
EPHX2 P34913 7/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
GAA P10253 2/20 0.47
POLB P06746 1/20 0.47
GFER P55789 1/20 0.47
NPC1 O15118 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
MAPT P10636 1/20 0.42
RAB9A P51151 1/20 0.41
GRIN2D O15399 1/20 0.40
GRIN3B O60391 1/20 0.40
GRIN1 Q05586 1/20 0.40
GRIN2A Q12879 1/20 0.40
GRIN2B Q13224 1/20 0.40
GRIN2C Q14957 1/20 0.40
GRIN3A Q8TCU5 1/20 0.40
PGR P06401 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21220794 0.91 LMNA (0.45) LMNAALDH1A1EPHX2MEN1KMT2A
SCHEMBL18317467 0.88 LMNA (0.55) LMNAALDH1A1EPHX2MEN1KMT2A
SCHEMBL28060058 0.83 LMNA (0.50) LMNAALDH1A1EPHX2MEN1KMT2A
SCHEMBL2763437 0.83 LMNA (0.77) LMNAALDH1A1EPHX2MEN1KMT2A
SCHEMBL548018 0.80 ALDH1A1 (0.36) LMNAALDH1A1EPHX2GRIN2DGRIN3B
SCHEMBL996302 0.79 GRIN2D (0.44) LMNAALDH1A1MEN1KMT2ANPC1
SCHEMBL19813742 0.77 LMNA (0.47) LMNAALDH1A1EPHX2MEN1KMT2A
SCHEMBL6637675 0.77 ALDH1A1 (0.47) LMNAALDH1A1EPHX2MEN1KMT2A
SCHEMBL18317663 0.77 MEN1 (0.44) LMNAALDH1A1EPHX2MEN1KMT2A
SCHEMBL181479 0.76 GRIN2D (0.62) LMNAALDH1A1EPHX2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 946 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116535329-A Synthetic method of NOBIN-type axial chiral biaryl compound and compound thereof 湖南师范大学 2023-08-04 CN claimed
CN-115811921-A Organic electroluminescent device 长春海谱润斯科技股份有限公司 2023-03-17 CN claimed
EP-2915824-B1 METALLOCENE LIGANDS, METALLOCENE COMPOUNDS AND METALLOCENE CATALYSTS, THEIR SYNTHESIS AND THEIR USE FOR THE POLYMERIZATION OF OLEFINS LUMMUS NOVOLEN TECHNOLOGY GMBH (DE) 2022-05-25 EP claimed
EP-2915824-A1 METALLOCENE LIGANDS, METALLOCENE COMPOUNDS AND METALLOCENE CATALYSTS, THEIR SYNTHESIS AND THEIR USE FOR THE POLYMERIZATION OF OLEFINS Lummus Novolen Technology Gmbh (DE) 2015-09-09 EP claimed
EP-2456435-B1 HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE UNIV LELAND STANFORD JUNIOR (US) 2015-06-24 EP claimed
EP-1548023-B1 Transition metal compound, catalyst system and the use of the latter for the polymerisation and copolymerisation of olefins BASELL POLYOLEFINE GMBH (DE) 2013-08-14 EP claimed
US-8415492-B2 Metallocene compounds, catalysts comprising them, process for producing an olefin polymer by use of the catalysts, and olefin homo- and copolymers LUMMUS NOVOLEN TECHNOLOGY GMBH (DE) 2013-04-09 US claimed
US-20120329964-A1 METALLOCENE COMPOUNDS, CATALYSTS COMPRISING THEM, PROCESS FOR PRODUCING AN OLEFIN POLYMER BY USE OF THE CATALYSTS, AND OLEFIN HOMO- AND COPOLYMERS LUMMUS NOVOLEN TECHNOLOGY GMBH (DE) 2012-12-27 US claimed
US-20120225862-A1 HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE AUCKLAND UNIVSERVICES LIMITED (NZ) 2012-09-06 US claimed
EP-2456435-A1 HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE The Board of Trustees of The Leland Stanford Junior University (US) 2012-05-30 EP claimed
US-6444606-B1 CATALYST SYSTEM COMPRISING AT LEAST ONE METALLOCENE COMPONENT, AT LEAST ONE COCATALYST AND AT LEAST ONE SUPPORT BASELL POLYPROPYLEN GMBH (DE) 2002-09-03 US claimed
US-6432993-B1 BENZIMIDAZOLE OR IMIDAZO(4,5-B)PYRIDINE DERIVATES; IMMUNOMODULATORS; ALDOSE REDUCTASE AND LIPOXYGENASE INHIBITORS; DIABETES; PREVENTS LIPID PEROXIDATION; ANTILIPEMIC, HYPOTENSIVE AGENTS SANKYO COMPANY, LIMITED (JP) 2002-08-13 US claimed
WO-2001048034-A2 TRANSITION METAL COMPOUND, LIGAND SYSTEM, CATALYST SYSTEM AND THE USE OF THE LATTER FOR THE POLYMERISATION AND COPOLYMERISATION OF OLEFINS BASELL POLYOLEFINE GMBH (DE) 2001-07-05 WO claimed
EP-1082363-A1 ORGANOMETAL COMPOUND, CATALYST SYSTEM CONTAINING SAID ORGANOMETAL COMPOUND AND ITS USE Basell Polyolefine GmbH (DE) 2001-03-14 EP claimed
CN-1280570-A Substituted fused heterocyclic compounds SANKYO CO (JP) 2001-01-17 CN claimed
WO-2000044799-A1 ORGANOMETAL COMPOUND, CATALYST SYSTEM CONTAINING SAID ORGANOMETAL COMPOUND AND ITS USE TARGOR GMBH (DE) 2000-08-03 WO claimed
EP-1022272-A1 SUBSTITUTED FUSED HETEROCYCLIC COMPOUNDS Sankyo Company Limited (JP) 2000-07-26 EP claimed
EP-0942938-A1 SUPPORTED CATALYST SYSTEM, METHOD FOR THE PRODUCTION AND USE THEREOF IN OLEFIN POLYMERIZATION Basell Polyolefine GmbH (DE) 1999-09-22 EP claimed
WO-1998040416-A1 SUPPORTED CATALYST SYSTEM, METHOD FOR THE PRODUCTION AND USE THEREOF IN OLEFIN POLYMERIZATION TARGOR GMBH (DE) 1998-09-17 WO claimed
US-4691051-A Adamantyl phenyl β-alanines PENNWALT CORPORATION (US) 1987-09-01 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329964-A1 METALLOCENE COMPOUNDS, CATALYSTS COMPRISING THEM, PROCESS FOR PRODUCING AN OLEFIN POLYMER BY USE OF THE CATALYSTS, AND OLEFIN HOMO- AND COPOLYMERS PIN1, PCNA, OPRM1 LMNA 3102/4885ALDH1A1 3312/4885EPHX2 1548/4885
US-20120225862-A1 HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE BRDT, NISCH, PAICS LMNA 575/4885ALDH1A1 1336/4885EPHX2 326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.